undamentalytics Newsletter

Penczek Ronald W: insider trades

Officer at Elevance Health. No open-market purchases and 23 sales not made under a pre-set plan, reported from August 5, 2016 to June 15, 2026.

What happened after Penczek Ronald W’s sales?

After their sales, the shares moved +5.2% against the index over 12 months on average (a negative figure means selling was the right call); 33% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Penczek Ronald W: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 23 +0.4% +2.3% 39% 11 −0.37 0.72 No reliable evidence
Sales, 12 months after the report 21 +5.2% +9.3% 33% 10 −0.19 0.86 No reliable evidence
Sales, 12 months after the trade 21 +5.9% +7.5% 38% 10 −0.16 0.88 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Elevance Health ELV CAO & Controller023August 5, 2016June 15, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
June 15, 2026June 12, 2026 ELV Sale $148,766 +3.4%not yetnot yet
May 20, 2026May 19, 2026 ELV Sale $617,192 −0.2%not yetnot yet
March 11, 2025March 10, 2025 ELV Sale $183,903 −14.8%−47.4%−49.8%
March 8, 2024March 6, 2024 ELV Sale $462,195 +1.0%−25.7%−28.8%
December 1, 2023November 30, 2023 ELV Sale $501,304 −7.3%−51.0%−47.4%
October 26, 2023October 24, 2023 ELV Sale $29,078 −8.1%−49.4%−44.8%
March 3, 2022March 3, 2022 ELV Sale $1,123,497 +8.4%+5.3%+7.5%
February 8, 2022February 7, 2022 ELV Sale $1,252,965 +18.3%+15.3%+15.4%
October 29, 2021October 28, 2021 ELV Sale $501,400 +3.8%+43.5%+40.7%
March 8, 2021March 5, 2021 ELV Sale $690,588 +8.0%+28.9%+30.5%
March 5, 2021March 4, 2021 ELV Sale $21,679 +4.0%+24.1%+30.5%
November 10, 2020November 9, 2020 ELV Sale $396,569 −20.4%+3.0%+1.4%
June 10, 2020June 8, 2020 ELV Sale $162,268 −12.6%+3.6%−0.7%
November 14, 2019November 12, 2019 ELV Sale $334,866 −6.7%−5.2%−2.1%
May 31, 2019May 30, 2019 ELV Sale $212,877 −12.2%−6.7%−4.1%
September 6, 2018September 4, 2018 ELV Sale $202,622 +11.4%−11.8%−8.5%
March 9, 2018March 7, 2018 ELV Sale $455,925 +1.0%+30.3%+26.2%
November 9, 2017November 7, 2017 ELV Sale $212,637 +3.7%+23.6%+24.4%
June 8, 2017June 7, 2017 ELV Sale $162,528 +2.3%+9.3%+7.5%
March 7, 2017March 3, 2017 ELV Sale $120,694 +10.6%+21.9%+25.4%
March 3, 2017March 1, 2017 ELV Sale $202,041 +9.9%+25.3%+27.1%
November 22, 2016November 22, 2016 ELV Sale $113,398 +7.3%+35.5%+38.3%
August 5, 2016August 3, 2016 ELV Sale $70,860 −2.3%+37.2%+35.8%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Penczek Ronald W traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.